Drug Trial Radar · NCT03992755
Extension Study for Participants in LIQ861 Trials to Evaluate the Long-term Safety of Dry Powder Inhalation of Treprostinil
Last checked: Nov 20, 2026Latest source record: Jan 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
92
Actual
Start
Jul 18, 2019
Primary completion
May 31, 2025
Study completion May 31, 2025
Sponsor
- Lead sponsor
- Liquidia Technologies, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Nuventra, Inc.
- First posted
- Jun 20, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to evaluate the long-term safety of LIQ861 in patients with pulmonary arterial hypertension (PAH).
Conditions
- Primary Pulmonary Hypertension
Interventions
LIQ861 Inhaled TreprostinilDrug
LIQ861 bulk powder is generated from a treprostinil/excipient matrix from which particles of precise size and shape are created and filled into a hydroxypropyl methylcellulose (HPMC) capsule (size 3). LIQ861 capsules are provided in capsule strengths of 25 μg, 50 μg, 75 μg and 100 μg treprostinil.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with treatment emergent adverse events (AEs).Time frame: Baseline until the end of study, approximately 2.5 years (Dec-2021).
Locations
25 sites in 1 country. Site status is shown where the registry gives one.
Banner University Medical Center
Phoenix, Arizona
Arizona Pulmonary Specialists, Ltd.
Phoenix, Arizona
West Los Angeles VA Healthcare Center
Los Angeles, California
UC Davis Medical Center
Sacramento, California
Los Angeles Biomedical Research Center
Torrance, California
University of Colorado Anschutz Medical Campus
Aurora, Colorado
University of Florida
Gainesville, Florida
Mayo Clinic-Jacksonville
Jacksonville, Florida
AdventHealth
Orlando, Florida
Emory University School of Medicine
Atlanta, Georgia
Northwestern Medicine, Feinberg School of Medicine
Chicago, Illinois
University of Chicago Medicine
Chicago, Illinois
University of Kansas Medical Center
Kansas City, Kansas
Ochsner Medical Center
New Orleans, Louisiana
Tufts Medical Center
Boston, Massachusetts
Mayo Clinic-Rochester
Rochester, Minnesota
University of New Mexico Health Science Center
Albuquerque, New Mexico
University of Cincinnati Medical Center
Cincinnati, Ohio
Oregon Health and Science Center
Portland, Oregon
Alleghany General Hospital
Pittsburgh, Pennsylvania
UPMC Presbyterian Hospital
Pittsburgh, Pennsylvania
UT Southwestern Medical Center
Dallas, Texas
Houston Methodist Lung Center
Houston, Texas
University of Texas Health Science Center at San Antonio
San Antonio, Texas
INOVA Fairfax Medical Campus
Falls Church, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.